Pfizer Enbrel (Outside the U.S. and Canada) — Revenues: decreased by 22.9% to $138.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.4%, from $140.00M to $138.00M. Over 4 years (FY 2021 to FY 2025), Enbrel (Outside the U.S. and Canada) — Revenues: shows a downward trend with a -14.7% CAGR.
pfe_segment_enbrel_outside_the_u_s_and_canada_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $286.00M | $283.00M | $297.00M | $280.00M | $257.00M | $230.00M | $236.00M | $199.00M | $219.00M | $208.00M | $203.00M | $159.00M | $179.00M | $169.00M | $183.00M | $140.00M | $154.00M | $154.00M | $179.00M | $138.00M |
| QoQ Change | — | -1.0% | +4.9% | -5.7% | -8.2% | -10.5% | +2.6% | -15.7% | +10.1% | -5.0% | -2.4% | -21.7% | +12.6% | -5.6% | +8.3% | -23.5% | +10.0% | +0.0% | +16.2% | -22.9% |
| YoY Change | — | — | — | — | -10.1% | -18.7% | -20.5% | -28.9% | -14.8% | -9.6% | -14.0% | -20.1% | -18.3% | -18.8% | -9.9% | -11.9% | -14.0% | -8.9% | -2.2% | -1.4% |